Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (NASDAQ:IVA) (&#34;Inventiva&#34; or the &#34;Company&#34;), a clinical-stage biopharmaceutical company focused on the development of oral therapies for

Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Inventiva Halts Euronext Trading Ahead of Financing, Signals New Plan

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (NASDAQ:IVA) (&amp;#34;Inventiva&amp;#34; or the &amp;#34;Company&amp;#34;), a clinical-stage biopharmaceutical company focused on the development of oral therapies for</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Inventiva announced a temporary halt of its Euronext Paris listing ahead of a proposed financing, with details to be disclosed later. The halt, from 9:00 a.m. to about 3:30 p.m. CEST, coincides with the start of ADS trading on Nasdaq at 9:30 a.m. ET, creating near-term volatility as financing terms emerge for lanifibranor in NATiV3 Phase 3 for MASH.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Inventiva to suspend Euronext Paris listing ahead of financing; details to come.</li><li>Trading halt from 9:00 a.m. CEST; resume ~3:30 p.m. CEST; Nasdaq ADS start 9:30 a.m. ET.</li><li>Lanifibranor NATiV3 Phase 3 program for MASH; financing may affect plan.</li><li>IVA trades on Nasdaq; IVEVF OTC; Euronext Paris ticker IVA; cross-listing implications.</li><li>Forward-looking statements caution; no obligation to update; further communications to follow.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Inventiva S.A. (IVA (Nasdaq))</strong>: Primary US listing; trading halt ahead of financing may impact liquidity and valuation.</li><li><strong>Inventiva S.A. (IVA (Euronext Paris))</strong>: Eurozone listing halted; timing of resumption critical for local investor sentiment.</li><li><strong>Inventiva S.A. (IVEVF)</strong>: OTC listing; cross-list exposure may influence price linkage and arbitrage opportunities.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article centers on a trading halt ahead of a financing transaction, a classic corporate-financing catalyst with potential near-term price and liquidity effects across multiple listings.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Trading halt and pending financing details create immediate price volatility.</li><li>Resumption timing and cross-listing could affect liquidity and spread.</li><li>Financing terms may imply dilution or new equity raising pressures.</li><li>Cross-market dynamics between Nasdaq IVA and Euronext Paris IVA may drive arbitrage.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Inventiva (Nasdaq: IVA) announces temporary halt on Euronext Paris listing.</li><li>Halt duration: 9:00 a.m. to ~3:30 p.m. CEST; resumption expected today.</li><li>ADS trading on Nasdaq Global Market to begin at 9:30 a.m. ET under ticker IVA.</li><li>Financing transaction details to be provided in a new company communication.</li><li>Company focuses on lanifibranor, NATiV3 Phase 3 for MASH.</li><li>Listings: Euronext Paris (compartment B, IVA), OTC (IVEVF), Nasdaq Global Market (IVA).</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term IVA volatility remains high around the halt and financing news; outcomes depend on financing terms and potential dilution, within days.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify"><b>Daix (France), New York City (New York, United States), June 2, 2026 – </b><a href="https://www.globenewswire.com/Tracker?data=2BQveHG5REw-D22yFkAyp25HbrthrKbAgO94_CVkzVkzKyfOv_nlhs6rUEpd7Jh89SHVjcKzskYeJr9Olqb-iOY1Tpj-ui7tIXShbbApFdM=" rel="nofollow" target="_blank">Inventiva</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/IVA">IVA</a>) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announces that the listing of its ordinary shares on the regulated market of Euronext Paris will be temporarily halted, at the Company&#39;s request, from the opening of the market at 9:00 a.m. CEST.</p>  <p align="justify">This suspension comes ahead of a proposed financing transaction, details of which will be announced in a new communication of the Company.</p>  <p align="justify">This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume today, June 2, 2026, at approximately 3:30 p.m. CEST, which is the earliest time ADSs are expected to begin trading on the Nasdaq Global Market (9:30 a.m. ET), under the ticker symbol &#34;IVA&#34;.</p>  <p align="justify"><br></br><b>About Inventiva </b></p>  <p align="justify">Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.</p>  <p align="justify">Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris ((ticker: IVA, OTC:<a class="ticker" href="https://www.benzinga.com/quote/IVEVF">IVEVF</a>) and on the Nasdaq Global Market in the United States (ticker: IVA). <a href="https://www.globenewswire.com/Tracker?data=a_nCV2yrlrdhcLzFSYZmOzrumwhv4u7Cq21TDJDNILwhOG2uBQsmsoZQD3G68qREHfr-FhJuU660LZ5sVLiplBksQ2TOJ5X2w-u30fPCJHuc5JJVNX7qHHcCCcvXhBZh" rel="nofollow" target="_blank">https://www.inventivapharma.com</a></p>  <p align="justify"><b>Contacts</b></p> <table style="border-collapse: collapse; width:600px; border-collapse:collapse ;"><tr><td style="width:314px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; text-align: justify ;  vertical-align: middle; "><b>Media Relations</b><br></br><br></br><b>Pascaline Clerc:</b> <a href="mailto:media@inventivapharma.com" rel="nofollow" target="_blank">media@inventivapharma.com</a><br></br><br></br><b>Mark Corbae:</b> <a href="mailto:inventivapr@icrhealthcare.com" rel="nofollow" target="_blank">inventivapr@icrhealthcare.com</a></td><td style="width:314px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; text-align: justify ;  vertical-align: middle; "><b>Investor Relations</b><br></br><br></br><b>David Nikodem: </b><a href="mailto:IR@inventivapharma.com" rel="nofollow" target="_blank">IR@inventivapharma.com</a><br></br><br></br><b>Patricia L. Bank:</b> <a href="mailto:patti.bank@icrhealthcare.com" rel="nofollow" target="_blank">patti.bank@icrhealthcare.com</a></td></tr></table> <p align="justify"><b>Important Notice </b></p>  <p align="justify">This press release contains certain forward-looking statements with respect to the proposed trading halt. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. </p>  <p align="justify">Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.</p>  <p align="justify"><b>Disclaimers </b></p>  <p align="justify">This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>  <p align="justify">The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.</p> <p id="gnw_attachments_section-header">
    <strong>Attachment</strong>
</p>
<ul id="gnw_attachments_section-items">
            <li>
        <a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/1eea1f1d-fa92-42cd-a194-1aeaccf34349">Inventiva - PR - Trading Halt - EN - 06 02 2026</a>
      </li>
      </ul>
<img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE4NTMwNiM0MDI0MDIwODEjMjA4MjI0OQ=="></img> <br></br><img alt="" src="https://ml-eu.globenewswire.com/media/ZmYyYTAwZDktMjMyMC00NmI2LWIxNWQtZTg0ZGM4NzdlZjBhLTEwOTM4MjAtMjAyNi0wNi0wMi1lbg==/tiny/INVENTIVA.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/4e957060-eef5-4c1b-81e6-73683a4daa1e"><img src="https://ml-eu.globenewswire.com/media/4e957060-eef5-4c1b-81e6-73683a4daa1e/small/inventiva-logo-1200x630-png.png" border="0" width="150" height="79" alt="Primary Logo"></img></a></p>

Inventiva announced a temporary halt of its Euronext Paris listing ahead of a proposed financing, with details to be disclosed later. The halt, from 9:00 a.m. to about 3:30 p.m. CEST, coincides with the start of ADS trading on Nasdaq at 9:30 a.m. ET, creating near-term volatility as financing terms emerge for lanifibranor in NATiV3 Phase 3 for MASH.

Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News